2024 NaviFUS FUS Symposium Videos Now Available!
In 2024 September 22nd, we hosted the NaviFUS FUS Symposium, featuring groundbreaking advancements in NaviFUS technology and clinical research. Over 240 participants from around the world joined us for sessions on BBB Opening, Neuromodulation, and New Treatments, along with insightful panel discussions.
We’re excited to announce that all session recordings are now available on our Symposium YouTube channel! Don’t miss out on these transformative insights.
Technology System
NaviFUS has two products in development：
NaviFUS® Neuronavigator-guided transcranial focused ultrasound system
NaviFUS® – FUS system that uses ultrasound energy to open the BBB and for neuromodulation; the device has already passed preliminary safety testing.
NAVIRFA® Needle Tracking System
Precise Surgical Tracking Technology
NAVIRFA® – Optical 3D surgical guidance kit and software that can accurately visualize the spatial position of surgical needles in vivo through special imaging algorithms.
Partners & Investors
We are supported by great venture capital and healthcare investors, and we partner with international distributors, physicians, medical institutions, academic researchers, and patient advocacy groups around the world.
OUR PARTNERSHIPSINVESTOR RELATIONS
NaviFUS Latest News
See what we’ve been up to.
NaviFUS Epilepsy Clinical Study Featured by the Focused Ultrasound Foundation
The Focused Ultrasound Foundation featured NaviFUS’ recent Epilepsia publication on non-invasive focused ultrasound neuromodulation for drug-resistant epilepsy, highlighting the study’s clinical significance and continued development of the field.
Read more
Focused Ultrasound in the Spotlight: WIRED Highlights the Future of Noninvasive Brain Treatment
Focused ultrasound is opening new possibilities for how we reach and interact with the brain — without traditional surgery.
In a recent feature, WIRED explored the work of Dr. Ali Rezai and the WVU Rockefeller Neuroscience Institute (RNI), highlighting the evolving role of focused ultrasound in neurological and behavioral research.
NaviFUS Clinical Trial Published in Epilepsia
NaviFUS Corporation announced the online publication of “Low-intensity focused ultrasound neuromodulation for drug-resistant epilepsy: A randomized, sham-controlled crossover trial.” Conducted at Taipei Veterans General Hospital, the pilot, single-blind study enrolled 12 adults with drug-resistant epilepsy. Each participant completed both low-intensity focused ultrasound (LIFU) and sham treatment, allowing the study to evaluate individualized targeting, preliminary safety, clinical feasibility, and efficacy signals.
Read moreJoin Our Clinical Trials
NaviFUS is now enrolling participants for a new, non-invasive treatment using focused ultrasound for drug-resistant epilepsy and brain tumors.
No surgery. New hope.
Contact NaviFUS
Thank you for your interest in NaviFUS.
Feel free to contact us with any questions regarding collaboration.